TREATMENT OF HEPATITIS C VIRUS IN UNDERSERVED POPULATIONS

服务欠缺人群中丙型肝炎病毒的治疗

• 批准号: 7604188
• 负责人: BRIAN R. EDLIN
• 金额: $ 1.27万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604188
• 关键词: Antiviral Agents; Characteristics; Communities; Computer Retrieval of Information on Scientific Projects Database; Drug usage; Drug user; Evaluation; Funding; Grant; Hepatitis; Hepatitis C; Institution; Interferons; Medical; Outcome; Research; Research Personnel; Resources; Ribavirin; Safety; Site; Source; Treatment Protocols; Underserved Population; United States National Institutes of Health; Virus; base

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We propose to conduct a study to assess the feasibility of treating drug users for hepatitis C. We hypothesize that by maximizing facilitators and minimizing barriers to treatment we can enable drug users to receive effective treatment for hepatitis C. The specific aims are: 1. To estimate the proportions of drug uses referred from community-based field sites presenting for evaluation for hepatitis C treatment who (a) complete a medical evaluation for hepatitis C treatment, (b) receive antiviral treatment for hepatitis C, and (c) complete antiviral treatment for hepatitis C. 2. To describe the characteristics of drug users associated with completion of these outcomes. 3. To determine (i.e., describe qualitively and quantify) reasons for not starting treatment and for treatment discontinuation. 4. To describe the safety and efficacy of the pegylated interferon and ribavirin regimen in active drug users.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 我们建议开展一项研究，评估治疗吸毒者丙型肝炎的可行性。我们假设，通过最大限度地促进促进因素和最小化治疗障碍，我们可以使吸毒者获得有效的丙型肝炎治疗。具体目标是： 1. 估计从社区现场转介来接受丙型肝炎治疗评估的药物使用比例，这些人 (a) 完成丙型肝炎治疗的医学评估，(b) 接受丙型肝炎抗病毒治疗，以及 (c)丙型肝炎的完整抗病毒治疗。 2. 描述与完成这些结果相关的吸毒者的特征。 3. 确定（即定性描述和量化）不开始治疗和停止治疗的原因。 4. 描述聚乙二醇干扰素和利巴韦林治疗方案在活跃吸毒者中的安全性和有效性。